Literature DB >> 18598752

Anti-inflammatory neuropeptides: a new class of endogenous immunoregulatory agents.

Mario Delgado1, Doina Ganea.   

Abstract

Resolution of inflammation and induction of immune tolerance are essential to stabilize immune homeostasis and to limit the occurrence of exacerbated inflammatory and autoimmune conditions. Multiple mechanisms act together to ensure the re-establishment of immune homeostasis and maintenance of tolerance. The identification of endogenous factors that regulate these processes is crucial for the development of new therapies for inflammatory/autoimmune conditions. Neuropeptides produced during an ongoing inflammatory response emerged as endogenous anti-inflammatory agents that participate in processes leading to the resolution of inflammation and maintenance of tolerance. Anti-inflammatory neuropeptides and hormones such as vasoactive intestinal peptide, urocortin, adrenomedullin, melanocyte stimulating hormone, ghrelin, and cortistatin have beneficial effects in a variety of experimental inflammatory and autoimmune models. Their therapeutic effect has been attributed to their capacity to downregulate innate immunity, to inhibit antigen-specific T(H)1-driven responses, and to generate regulatory T cells. Finally, some of these neuropeptides have been identified as mediators of innate defense acting as natural antimicrobial peptides. Here we present the research findings in the neuropeptide immunoregulatory field, and examine possible therapies based on anti-inflammatory neuropeptides and hormones as a new pharmacologic platform.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18598752      PMCID: PMC2784101          DOI: 10.1016/j.bbi.2008.06.001

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  51 in total

Review 1.  Opportunities in somatostatin research: biological, chemical and therapeutic aspects.

Authors:  Gisbert Weckbecker; Ian Lewis; Rainer Albert; Herbert A Schmid; Daniel Hoyer; Christian Bruns
Journal:  Nat Rev Drug Discov       Date:  2003-12       Impact factor: 84.694

Review 2.  Points of control in inflammation.

Authors:  Carl Nathan
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

Review 3.  The significance of vasoactive intestinal peptide in immunomodulation.

Authors:  Mario Delgado; David Pozo; Doina Ganea
Journal:  Pharmacol Rev       Date:  2004-06       Impact factor: 25.468

4.  Enhanced delayed-type hypersensitivity and diminished immediate-type hypersensitivity in mice lacking the inducible VPAC(2) receptor for vasoactive intestinal peptide.

Authors:  E J Goetzl; J K Voice; S Shen; G Dorsam; Y Kong; K M West; C F Morrison; A J Harmar
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-06       Impact factor: 11.205

5.  Antimicrobial effects of alpha-MSH peptides.

Authors:  M Cutuli; S Cristiani; J M Lipton; A Catania
Journal:  J Leukoc Biol       Date:  2000-02       Impact factor: 4.962

6.  VIPase autoantibodies in Fas-defective mice and patients with autoimmune disease.

Authors:  Yogesh Bangale; Sangeeta Karle; Stephanie Planque; Yong-Xin Zhou; Hiroaki Taguchi; Yasuhiro Nishiyama; Lan Li; Ravishankar Kalaga; Sudhir Paul
Journal:  FASEB J       Date:  2003-04       Impact factor: 5.191

7.  Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide promote in vivo generation of memory Th2 cells.

Authors:  Mario Delgado; Javier Leceta; Doina Ganea
Journal:  FASEB J       Date:  2002-09-05       Impact factor: 5.191

8.  Roles of vasoactive intestinal peptide (VIP) in the expression of different immune phenotypes by wild-type mice and T cell-targeted type II VIP receptor transgenic mice.

Authors:  Julia K Voice; Carola Grinninger; Yvonne Kong; Yogesh Bangale; Sudhir Paul; Edward J Goetzl
Journal:  J Immunol       Date:  2003-01-01       Impact factor: 5.422

9.  Reduction in hypophyseal growth hormone and prolactin expression due to deficiency in ghrelin receptor signaling is associated with Pit-1 suppression: relevance to the immune system.

Authors:  Hyunwon Yang; Vishwa D Dixit; Kalpesh Patel; Bolormaa Vandanmagsar; Gary Collins; Yuxiang Sun; Roy G Smith; Dennis D Taub
Journal:  Brain Behav Immun       Date:  2008-06-17       Impact factor: 7.217

10.  alpha-Melanocyte-stimulating hormone inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production in leukocytes by modulating protein kinase A, p38 kinase, and nuclear factor kappa B signaling pathways.

Authors:  Sun-Woo Yoon; Sung-Ho Goh; Jang-Soo Chun; Eun-Wie Cho; Myung-Kyu Lee; Kil-Lyong Kim; Jae-Jin Kim; Chul-Joong Kim; Haryoung Poo
Journal:  J Biol Chem       Date:  2003-06-19       Impact factor: 5.157

View more
  30 in total

1.  Vascular Dysfunction in Pneumocystis-Associated Pulmonary Hypertension Is Related to Endothelin Response and Adrenomedullin Concentration.

Authors:  Dan W Siemsen; Erin Dobrinen; Soo Han; Kari Chiocchi; Nicole Meissner; Steve D Swain
Journal:  Am J Pathol       Date:  2015-12-11       Impact factor: 4.307

2.  NDP-MSH inhibits neutrophil migration through nicotinic and adrenergic receptors in experimental peritonitis.

Authors:  Jozi Figueiredo; Ana Elisa Ferreira; Rangel Leal Silva; Luis Ulloa; Paolo Grieco; Thiago Mattar Cunha; Sérgio Henrique Ferreira; Fernando de Queiróz Cunha; Alexandre Kanashiro
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-01-22       Impact factor: 3.000

Review 3.  Leveraging melanocortin pathways to treat glomerular diseases.

Authors:  Rujun Gong
Journal:  Adv Chronic Kidney Dis       Date:  2014-03       Impact factor: 3.620

Review 4.  Calcitonin gene-related peptide in the joint: contributions to pain and inflammation.

Authors:  David A Walsh; Paul I Mapp; Sara Kelly
Journal:  Br J Clin Pharmacol       Date:  2015-07-22       Impact factor: 4.335

Review 5.  Neuropeptides: keeping the balance between pathogen immunity and immune tolerance.

Authors:  Elena Gonzalez-Rey; Doina Ganea; Mario Delgado
Journal:  Curr Opin Pharmacol       Date:  2010-08       Impact factor: 5.547

6.  Promiscuous dimerization of the growth hormone secretagogue receptor (GHS-R1a) attenuates ghrelin-mediated signaling.

Authors:  Harriët Schellekens; Wesley E P A van Oeffelen; Timothy G Dinan; John F Cryan
Journal:  J Biol Chem       Date:  2012-11-16       Impact factor: 5.157

7.  Gene expression analysis of neuropeptides in oral mucosa during periodontal disease in non-human primates.

Authors:  John Ferrin; Sreenatha Kirakodu; David Jensen; Ahmad Al-Attar; Rebecca Peyyala; M John Novak; Dolph Dawson; Mohanad Al-Sabbagh; Arnold J Stromberg; Luis Orraca; Janis Gonzalez-Martinez; Armando Burgos; Jeffrey L Ebersole; Octavio A Gonzalez
Journal:  J Periodontol       Date:  2018-07-20       Impact factor: 6.993

8.  Comparison of the anti-inflammatory and anti-nociceptive effects of cortistatin-14 and somatostatin-14 in distinct in vitro and in vivo model systems.

Authors:  Adrienn Markovics; Éva Szoke; Katalin Sándor; Rita Börzsei; Teréz Bagoly; Ágnes Kemény; Krisztián Elekes; Erika Pintér; János Szolcsányi; Zsuzsanna Helyes
Journal:  J Mol Neurosci       Date:  2011-06-22       Impact factor: 3.444

9.  Novel, biocompatible, and disease modifying VIP nanomedicine for rheumatoid arthritis.

Authors:  Varun Sethi; Israel Rubinstein; Antonina Kuzmis; Helen Kastrissios; James Artwohl; Hayat Onyuksel
Journal:  Mol Pharm       Date:  2013-01-23       Impact factor: 4.939

10.  Effects of pituitary adenylate cyclase activating polypeptide on CD4(+)/CD8(+) T cell levels after traumatic brain injury in a rat model.

Authors:  Rong Hua; Shan-Shan Mao; Yong-Mei Zhang; Fu-Xing Chen; Zhong-Hai Zhou; Jun-Quan Liu
Journal:  World J Emerg Med       Date:  2012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.